Shaw Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-05-2024
- Paid Up Capital ₹ 0.32 M
as on 25-05-2024
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2020
- Revenue -76.84%
(FY 2017)
- Profit -35.54%
(FY 2017)
- Ebitda -50.88%
(FY 2017)
- Net Worth -48.81%
(FY 2017)
- Total Assets 5.88%
(FY 2017)
About Shaw Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.32 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Shaw, Bankim Shaw, Narendra Shaw, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232WB2005PTC106352
- Company No.
106352
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2005
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shaw Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bankim Shaw  | Managing Director | 25-Nov-2005 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sanjay Shaw | Whole-Time Director | 25-Nov-2005 | Current |
| Narendra Shaw | Whole-Time Director | 25-Nov-2005 | Current |
| Chandra Shaw | Whole-Time Director | 25-Nov-2005 | Current |
| Ashish Shaw | Whole-Time Director | 25-Nov-2005 | Current |
Financial Performance of Shaw Pharmaceuticals.
Shaw Pharmaceuticals Pvt Ltd, for the financial year ended 2017, experienced significant reduction in revenue, with a 76.84% decrease. The company also saw a substantial fall in profitability, with a 35.54% decrease in profit. The company's net worth observed a substantial decline by a decrease of 48.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shaw Pharmaceuticals?
In 2017, Shaw Pharmaceuticals had a promoter holding of 66.69% and a public holding of 33.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shaw Trading & Mfg. 1833 Private LimitedActive 3 years 6 monthsSanjay Shaw and Ashish Shaw are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shaw Pharmaceuticals?
Unlock and access historical data on people associated with Shaw Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shaw Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shaw Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
